Sign in →

Test Code MMLYP Antimicrobial Susceptibility Panel, Yeast, Varies

Infectious

Reporting Name

Susceptibility Panel, Yeast

Useful For

Determining in vitro quantitative antifungal susceptibility (minimum inhibitory concentration) of non-fastidious yeast

 

As an aid in the management of certain circumstances, such as:

-Refractory oropharyngeal infections due to Candida species in patients who appear to be experiencing therapeutic failure with standard agents at standard doses

-Invasive infections due to Candida species when the utility of azole antifungal agents is uncertain (eg, when the infection is due to a non-Candida albicans organism)

Additional Tests

Test ID Reporting Name Available Separately Always Performed
SYP Susceptibility Yeast Panel No, (Bill Only) Yes

Testing Algorithm

When this test is ordered, the susceptibility yeast panel will be performed at an additional charge. All yeast submitted will have susceptibility testing performed and billed as appropriate.

Method Name

Minimum Inhibitory Concentration (MIC)

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Varies


Shipping Instructions


1. See Infectious Specimen Shipping Guidelines

2. Place specimen in a large infectious container and label as an etiologic agent/infectious substance.



Necessary Information


Specimen source and suspected organism identification are required. If identification of organism is not provided, FUNID / Culture Referred for Identification, Fungus, Varies will be performed at an additional charge.



Specimen Required


Specimen Type: Organism in pure culture

Supplies: Infectious Container, Large (T146)

Container/Tube: Sabouraud's dextrose agar slant

Specimen Volume: Infecting yeast isolate

Collection Instructions: Organism must be in pure culture, actively growing. Do not submit mixed cultures.


Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Ambient (preferred)
  Refrigerated 

Reject Due To

Agar plate Reject

Reference Values

Results reported in mcg/mL

Day(s) Performed

Monday through Saturday

CPT Code Information

87186

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MMLYP Susceptibility Panel, Yeast 29577-4

 

Result ID Test Result Name Result LOINC Value
MMLYP Susceptibility Panel, Yeast 29577-4

Clinical Information

Candida species are the fourth leading cause of nosocomial infections and are frequent causes of community-acquired infections.

 

Antifungal susceptibility testing may aid in the management of patients with invasive infections due to Candida species or patients who appear to be experiencing therapeutic failure.

 

The Clinical Laboratory Standards Institute has approved the use of a broth microdilution method for determining the susceptibility of Candida species.

Interpretation

The Clinical and Laboratory Standards Institute method, breakpoints, and interpretive criteria are used.

Cautions

The assay cannot be used for minimum inhibitory concentration determinations for the dimorphic yeast or filamentous fungi.

Method Description

Yeast susceptibility is determined by colorimetric microdilution broth method using TREK Sensititre YeastOne Y011 Susceptibility Plate. Each plate is setup with appropriate dilutions of antifungal agents and a colorimetric indicator. After inoculation with a standardized suspension of organism in inoculum medium and incubation at 35° C for 24 to 48 hours; the minimum inhibitory concentrations for the test organism are determined by observing the lowest antifungal concentration showing inhibition of growth as evidenced by no color change of the test medium.(Clinical and Laboratory Standards Institute [CLSI]: Performance Standards for Antifungal Susceptibility Testing of Yeasts. 2nd ed. CLSI supplement M60. CLSI; 2020; CLSI: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI standard M27. CLSI; 2017)

Report Available

3 to 7 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.